Astellas' fezolinetant headed for Phase III

Astellas plans to start Phase III testing this year of fezolinetant to treat vasomotor symptoms in postmenopausal women after reporting that the therapy met the four co-primary endpoints in a Phase IIb trial.

Astellas Pharma Inc. (Tokyo:4503) said that compared with placebo "most" dose levels of oral fezolinetant significantly decreased the mean frequency and severity of vasomotor symptoms from baseline to week four and to week 12...